Join
Live feed
·
PRReleasevia Quantisnow
PTC Therapeutics Inc. logo

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

ByQuantisnow·Wall Street's wire, on your screen.
PTCT· PTC Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTCT (PTC Therapeutics Inc.) and more on Quantisnow.